Retatrutide is an "triple-G" receptor agonist that provides substantial weight loss, dramatic reductions in liver and visceral fat, and improved blood sugar control. By simultaneously targeting the GLP-1, GIP, and glucagon hormone receptors, it suppresses appetite while actively increasing energy expenditure and fat breakdown. 

Weight Loss and Metabolic Effects

• Profound weight reduction: Clinical trials show average body weight losses of up to 26% to 28.7% over 68 weeks at higher doses (12mg), outperforming older single or dual receptor medications. 

• Visceral fat decrease: Deep abdominal fat wrapping around organs drops significantly (up to 48.3%), which helps lower the long-term risk of heart disease and diabetes.

• Blood sugar control: Enhances insulin secretion and glucose stability, with high percentages of prediabetic trial participants returning to normal blood sugar ranges.

Organ Health and Physical Improvements

• Liver fat clearance: Demonstrates dramatic reductions (81% to 86%) in liver fat for individuals suffering from metabolic-associated steatotic liver disease (MASLD).

• Cardiovascular markers: Improves cholesterol profiles (lowering triglycerides and LDL particles) and reduces strain on blood pressure.

• Joint relief: Early observations indicate reduced knee osteoarthritis pain and improved physical mobility due to lowered body weight load

• 20mg 3ml prefilled pen

• Reconstituted (Liquid): Store at 4°C (refrigerated) and use within 12 weeks. Avoid repeated freeze-thaw cycles.